Velpatasvir
Hepatitis C protease inhibitor / Velpatasvir is an extremely potent pan-genotypic hepatitis C virus (HCV) NS5A inhibitor.1 It is a component of Epclusa® and Vosevi®, two clinically useful medications with 98% and 97%, respectively, cure rates for HCV. It displayed EC50’s for GTs 1-4, 6a ranging from 6-16 pM, GT5a at 75 pM, and GT6e at 130 pM. Velpatasvir also displayed an excellent barrier to viral resistance. It has been shown in silico, that velpatasvir binds to the SARS-CoV-2 spike protein and may be a potential therapeutic.2
Biochemicals & reagents
1377049-84-7
GS-5816
1) Link et al. (2019), Discovery of velpatasvir (GS-5816): A potent pan-genotypic HCV NS5A inhibitor in the single-tablet regimens Vosevi® and Epclusa®; Bioorg. Med. Chem. Lett., 29 2415 2) Kadioglu et al. (2020), Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning; [preprint] Bull. World Health Organ. E-pub: 21 March 2020
-20°C
TARGET: Protease -- DISEASE AREA: Infectious disease